MEDIAN Technologies boosts its presence in the US and announces major expansion of its subsidiary MEDIAN Technologies Inc.
- Opening of a new facility in Woburn, near Boston, Massachusetts
- Increased operational capacity for MEDIAN Technologies Inc.
- Ambitious recruitment plan for the US
MEDIAN Technologies (ALMDT.PA), a leading medical imaging solutions and service provider for image interpretation and management in oncology, today announced its US expansion plans with the opening of a major facility for its US subsidiary MEDIAN Technologies Inc. The new site in Woburn, Massachusetts will bring together all of the teams located around the Boston area and has the capacity to handle the ambitious US recruitment plan over the coming months. With this new space and expected employee growth, MEDIAN Technologies Inc. demonstrates a major increase in its operational capacity for the management of imaging projects in clinical trials.
“By strengthening our presence in the US through MEDIAN Technologies Inc., we will be able to provide the best possible service to our US customer base. In 2015, 43.5% of our revenue was produced in North America. A more permanent, stronger establishment in the US market was an essential step for us. We had also made this commitment to our investors and customers. It’s now a done deal,” said Fredrik Brag, CEO of MEDIAN Technologies “The Boston area is an extraordinary breeding ground for all the biopharmaceutical industry players, particularly in the field of oncology. Large pharmaceutical companies and biotechnology companies, which are either already our customers or potential customers, are very present in the region. This will provide us with great momentum and help fuel our on-going growth.”
The facility, Trade Center 128, located at 300 Trade Center, Suite 5610, 01801 Woburn, MA, USA will be operational as of May 16, 2016.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”